Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
KYTHERA BIOPHARMACEUTICALS INC (KYTH)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-15 | Mar-31-15 | Dec-31-14 | Sep-30-14 | Jun-30-14 | Mar-31-14 | Dec-31-13 | Sep-30-13 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues [+] | 0.3 | 0.0 | 132.4 | 0.0 | 0.0 | 0.0 | 50.5 | 0.0 |
| Royalties | 11.2 | 15.3 | | 13.4 | 11.0 | 10.0 | | 7.0 |
| Products | 0.3 | | | | | | | |
| Revenue growth | | | 162.3% | | | | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.3 | 0.0 | 132.4 | 0.0 | 0.0 | 0.0 | 50.5 | 0.0 |
| Gross margin | 95.1% | | 100.0% | | | | 100.0% | |
| Selling, general and administrative [+] | 25.0 | 12.5 | 9.7 | 7.9 | 7.4 | 6.1 | 4.4 | 4.0 |
| General and administrative | | | 9.7 | 7.9 | | | 4.4 | 4.0 |
| Research and development | 11.2 | 15.3 | 13.5 | 13.4 | 11.0 | 10.0 | 9.2 | 7.0 |
| Other operating expenses | | | 132.4 | | | | 50.5 | |
| EBITDA [+] | -35.7 | -27.6 | -23.0 | -21.2 | -18.3 | -16.1 | -13.5 | -11.0 |
| EBITDA growth | 95.2% | 71.6% | 69.9% | 93.3% | 56.3% | 18.0% | -23.0% | -32.1% |
| EBITDA margin | -12408.3% | | -17.4% | | | | -26.8% | |
| Depreciation and amortization | 0.2 | 0.2 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBIT [+] | -35.9 | -27.8 | -23.2 | -21.3 | -18.3 | -16.1 | -13.6 | -11.0 |
| EBIT growth | 96.1% | 72.4% | 70.7% | 93.7% | 56.1% | 17.0% | -23.7% | -32.7% |
| EBIT margin | -12475.3% | | -17.5% | | | | -26.9% | |
| Non-recurring items [+] | | | | | | 52.8 | | |
| In-process research & development | | | | | | 52.8 | | |
| Interest expense, net [+] | 1.2 | 1.1 | 1.0 | 1.2 | 1.2 | 0.6 | 0.5 | 0.5 |
| Interest expense | 1.3 | 1.1 | 1.1 | 1.2 | 1.2 | 0.7 | 0.5 | 0.5 |
| Interest income | 0.1 | 0.0 | 0.1 | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 |
| Other income (expense), net | | | -0.1 | | | | | |
| Pre-tax income | -37.2 | -28.8 | -24.2 | -22.5 | -19.5 | -69.4 | -14.0 | -11.5 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -37.2 | -28.8 | -24.2 | -22.5 | -19.5 | -69.4 | -14.0 | -11.5 |
| Net margin | -12900.7% | | -18.3% | | | | -27.8% | |
| |
| Basic EPS [+] | ($1.44) | ($1.24) | ($1.08) | ($0.99) | ($0.86) | ($3.18) | ($0.73) | ($0.62) |
| Growth | 67.0% | -61.0% | 47.3% | 60.7% | 29.2% | 312.8% | -80.0% | -94.6% |
| Diluted EPS [+] | ($1.44) | ($1.24) | ($1.08) | ($0.99) | ($0.86) | ($3.18) | ($0.73) | ($0.62) |
| Growth | 67.0% | -61.0% | 47.3% | 60.7% | 29.2% | 312.8% | -80.0% | -94.6% |
| |
| Shares outstanding (basic) [+] | 25.9 | 23.2 | 22.5 | 22.7 | 22.7 | 21.8 | 19.2 | 18.7 |
| Growth | 14.2% | 6.4% | 17.3% | 21.5% | 23.0% | 19.1% | 288.9% | 1199.9% |
| Shares outstanding (diluted) [+] | 25.9 | 23.2 | 22.5 | 22.7 | 22.7 | 21.8 | 19.2 | 18.7 |
| Growth | 14.2% | 6.4% | 17.3% | 21.5% | 23.0% | 19.1% | 288.9% | 1199.9% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|